
Sanofi and Regeneron were touted as having a sure-fire blockbuster on their hands when they first brought Praluent to market …

“Jon’s appointment comes at an exciting time for the company” reads the company press on annoucing its new Managing Director …

Porton Biopharma Limited (PBL) has officially opened the doors of its new fermentation facility. John Glen, MP for Salisbury and …

Ahead of World Ovarian Cancer Day on 8 May, new figures have been released suggesting that rates of this type …

United Therapeutics is set to acquire speciality pharma firm SteadyMed after it emerged that the pair had signed a definitive …

Building on the back of strong data released at the end of last year, Novartis has released further positive Phase …

Immuno-oncology has become a huge area of the oncology market, led by the wave of PD-1/L1 drugs that are reaping …

Dan Vahdat, CEO and Co-founder of Medopad, discusses the rapid expansion of the app he helped develop, as its mobile …

Roche’s Perjeta has edged one step closer to approval as a combo therapy after the EMA’s Committee for Medicinal Products …

Alzheon, a tiny biotech based in the Boston area, had initially launched its roadshow for an IPO potentially worth up …

Allergan has revealed new data from the second of two Phase 3 studies into the efficacy of its calcitonin gene-related …

The US has upped the ante against Canada to secure stronger border checks for pharmaceutical goods by adding the country …

Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown …

With the retirement of Elias Zerhouni as Head of Global R&D, Sanofi had to find a suitable replacement and believes …

The year seems like it’s running away as we come to the end of April. It’s been a more tense …